Fig. 1.
![Fig. 1. Time to disease progression and death correlates with the bone marrow plasma cell labeling index in plateau phase MM. / In patients with stable, treated MM and less than 10% residual monoclonal plasma cells, progression-free survival (A) and overall survival (B) are significantly worse in patients with a high PCLI in comparison to those with a low PCLI (median, 8 versus 39 months [P < .0001] and 20 versus 56 months [P < .0001], respectively).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/97/8/10.1182_blood.v97.8.2522/5/h80810940001.jpeg?Expires=1735558280&Signature=IHzUuq7AQ7iZyc3PAQBGw3r8CGFd3Pyp7irzi416ckVRxI~LYYiwY6EbxvX0BKPSMoIXISGYY-b0tNBtGMoCL6C5HHkKDLcdC6MWroRE7~dMT--XfmflB687pvpLyrmdL8dq6Q9hmwL6hXOpYKf6gq~sKgndbvy5B3Iy-ySYfYi6W~gYra4WStZPbwBK5K2tWozD2U8oSTi5ZzvzHHyoLSHonSIoUUVafMmBbWulrRRsWRad7RJbr1uRzC7fSQCduCQ-PabJQz~Rc-tvUHjziBLwTX7KNa6qkFTVuF6PNPxNQHrg1TLurqCLXstsgX4vltfnB8bSfsFlo1BbXJHP3Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Time to disease progression and death correlates with the bone marrow plasma cell labeling index in plateau phase MM.
In patients with stable, treated MM and less than 10% residual monoclonal plasma cells, progression-free survival (A) and overall survival (B) are significantly worse in patients with a high PCLI in comparison to those with a low PCLI (median, 8 versus 39 months [P < .0001] and 20 versus 56 months [P < .0001], respectively).
